BPC-157 vs KPV
Side-by-Side Comparison
| Attribute | Bpc 157 | Kpv |
|---|---|---|
| Category | Healing & Recovery | Anti-Inflammatory / Immune |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and... | KPV exerts anti-inflammatory effects through a mechanism distinct from the parent α-MSH hormone. Rather than acting through melanocortin receptors (which would trigger pigmentation), KPV is... |
| Evidence Rating | C — Phase I–II Clinical Trials | D — Preclinical |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | Preclinical. No formal clinical trials completed. Used in compounding pharmacy protocols. Removed from FDA Category 2 on April 15, 2026. |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | No significant adverse effects reported in preclinical studies; Does not cause skin darkening (unlike Melanotan peptides) |
| Route | Subcutaneous (preferred), Intramuscular, or Oral | Oral (gut), Subcutaneous (systemic), Topical (skin) |
| Dose Range | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials | Oral: 200-500 mcg/day; SC: 100-500 mcg/day; Topical: 0.01-0.1% preparation |
| Frequency | Once daily | 1-2 times daily |
| Molecular Weight | ~1419.5 g/mol | ~342.4 g/mol |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | ~2 hours (SC); shorter oral due to GI degradation |
Overview
BPC-157 and KPV are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
KPV — Mechanism & Evidence
KPV is a naturally occurring tripeptide (Lys-Pro-Val, MW ~342.4 g/mol) derived from the C-terminal region (positions 11–13) of alpha-melanocyte-stimulating hormone (α-MSH). It retains potent anti-inflammatory and antimicrobial properties of the full-length hormone without activating melanocortin receptors responsible for skin pigmentation or sexual arousal. KPV suppresses NF-κB activation and is transported into intestinal epithelial cells via the PepT1 transporter, which is upregulated during gut inflammation — creating a self-targeting mechanism. Its small size enables oral bioavailability, which is unusual for peptides. It was among the 12 peptides removed from FDA Category 2 on April 15, 2026.
Key claims: Reduces intestinal inflammation; Anti-inflammatory without pigmentation; Wound healing and skin benefits.
Shared Research Applications
Both peptides are studied for: Gut Health.
BPC-157 is also researched for: Injury Recovery.
KPV is also researched for: Immune Support.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
KPV: No significant adverse effects reported in preclinical studies Does not cause skin darkening (unlike Melanotan peptides) No formal human safety trials have been conducted
Related Products
Related Research News
BPC-157 Gut Health: Gastric Cytoprotection Studies
Research on BPC-157 began with gastric cytoprotection in the early 1990s, led by Sikiric and colleagues at the University of Zagreb. Studies show it protects against ethanol-induced lesions and NSAID damage in rat models, with effects linked to angiogenesis, prostaglandins, nitric oxide, and gut-brain signaling. This body of work highlights its stability for oral use and broad preclinical applications in GI models.
KPV Peptide Research Guide: Synthesis, Uses and Lab Safety
KPV peptide, a tripeptide of lysine, proline and valine with formula C12H22N4O4, shows anti-inflammatory effects in studies on bowel disease and wound healing. Labs produce it mainly via solid-phase peptide synthesis, confirmed pure by HPLC and mass spectrometry. Proper storage, quality checks and regulatory compliance ensure reliable research outcomes.
BPC-157 Shelf Life: Lyophilized vs Reconstituted Stability Guide
BPC-157 has a finite shelf life that varies by form and storage. Lyophilized powder lasts 12-18 months refrigerated or 24+ months frozen, while reconstituted solution holds for about 28 days under refrigeration. Factors like temperature, light, and handling influence stability, and researchers should watch for signs of degradation to ensure reliable results.